Ebola Treatments: FDA, NIH Developing New Clinical Trial Protocol
This article was originally published in The Pink Sheet Daily
FDA inks agreement with WHO to allow exchange of non-public information about medical products.
You may also be interested in...
As part of the new Coronavirus Treatment Acceleration Program, FDA staff also are being reassigned to handle investigational therapy requests faster.
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.